15 results
6-K
EX-1.1
OBSVF
ObsEva SA
22 Jun 18
ObsEva Announces Launch of ProposedFollow-on Public Offering
4:06pm
is terminated, the Company will pay or cause to be paid all costs and expenses incident to the performance of its obligations hereunder, including without … limitation, (i) the costs incident to the authorization, issuance, sale, preparation and delivery of the Shares and any taxes payable in that connection
6-K
EX-1.1
OBSVF
ObsEva SA
5 Mar 21
Current report (foreign)
8:15am
, including oversight, access controls, encryption, technological and physical safeguards, business continuity/disaster recovery and incident response … contemplated hereby, including without limitation (i) all expenses incident to the issuance and delivery of the Shares (including all printing
6-K
EX-1.1
OBSVF
ObsEva SA
8 Sep 20
ObsEva Announces $20.0 Million Underwritten Offering and Concurrent Private Placement
7:40am
are consummated or this Agreement is terminated, the Company will pay or cause to be paid all costs, fees and expenses incident to the performance of its … obligations hereunder and in connection with the transactions contemplated hereby, including without limitation, (i) the costs incident
6-K
EX-99.5
OBSVF
ObsEva SA
13 Oct 21
ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix
9:27am
shareholders of the shares of Common Stock. We will bear all fees and expenses incident to our obligation to register the shares of Common Stock
6-K/A
EX-99.5
OBSVF
ObsEva SA
13 Oct 21
ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix
5:24pm
shareholders of the shares of Common Stock. We will bear all fees and expenses incident to our obligation to register the shares of Common Stock
424B7
lof2vdq
23 Nov 21
Prospectus with selling stockholder info
4:06pm
424B7
31arqyuxulamd1vampjt
3 Mar 22
Prospectus with selling stockholder info
4:43pm
F-3
comkrg6s ez
10 Nov 21
Shelf registration (foreign)
5:23pm
F-3
72mfy7gk11xvvi
17 Feb 22
Shelf registration (foreign)
4:14pm
10-K
7cv 00y36
31 Mar 23
Annual report
4:01pm
6-K/A
EX-99.2
qpv0dz2xlkeukc4lx
13 Oct 21
ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix
5:24pm
6-K
EX-99.3
50y7uf3cntkq3yac
28 Jan 22
ObsEva Announces Corporate Updates
5:16pm
6-K
EX-99.2
739r uvkwk
13 Oct 21
ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix
9:27am
- Prev
- 1
- Next